NO952761L - Piperidinestere, fremgangsmåte for deres fremstilling og anvendelse som terapeutika - Google Patents

Piperidinestere, fremgangsmåte for deres fremstilling og anvendelse som terapeutika

Info

Publication number
NO952761L
NO952761L NO952761A NO952761A NO952761L NO 952761 L NO952761 L NO 952761L NO 952761 A NO952761 A NO 952761A NO 952761 A NO952761 A NO 952761A NO 952761 L NO952761 L NO 952761L
Authority
NO
Norway
Prior art keywords
therapeutics
preparation
methods
piperidine esters
piperidine
Prior art date
Application number
NO952761A
Other languages
English (en)
Other versions
NO304427B1 (no
NO952761D0 (no
Inventor
Jean Paul Thenot
Jonathan R Frost
Patrick Lardenois
Maria Carmen Renones
Alexander Wick
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of NO952761D0 publication Critical patent/NO952761D0/no
Publication of NO952761L publication Critical patent/NO952761L/no
Publication of NO304427B1 publication Critical patent/NO304427B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO952761A 1994-07-13 1995-07-12 Piperidinester og medikament og farmas°ytisk preparat omfattende denne NO304427B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9408711A FR2722497B1 (fr) 1994-07-13 1994-07-13 Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique

Publications (3)

Publication Number Publication Date
NO952761D0 NO952761D0 (no) 1995-07-12
NO952761L true NO952761L (no) 1996-01-15
NO304427B1 NO304427B1 (no) 1998-12-14

Family

ID=9465359

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952761A NO304427B1 (no) 1994-07-13 1995-07-12 Piperidinester og medikament og farmas°ytisk preparat omfattende denne

Country Status (19)

Country Link
US (1) US5620990A (no)
EP (1) EP0692472A1 (no)
JP (1) JPH0859616A (no)
KR (1) KR960004322A (no)
CN (1) CN1120038A (no)
AU (1) AU695312B2 (no)
CA (1) CA2153726A1 (no)
CZ (1) CZ180795A3 (no)
FI (1) FI953410A7 (no)
FR (1) FR2722497B1 (no)
HU (1) HU215599B (no)
IL (1) IL114562A (no)
NO (1) NO304427B1 (no)
NZ (1) NZ272552A (no)
PL (1) PL309589A1 (no)
RU (1) RU95113144A (no)
SK (1) SK88795A3 (no)
TW (1) TW374084B (no)
ZA (1) ZA955801B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701282A (es) * 1994-08-18 1997-05-31 Pfizer Fenoles neuroprotectores.
CN1278167A (zh) 1997-10-27 2000-12-27 住友制药株式会社 酰胺衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
FR2628740B3 (fr) * 1989-04-12 1990-01-19 Synthelabo Procede de preparation des enantiomeres du (chloro-4 phenyl)-1 (((fluoro-4 phenyl)methyl)-4 piperidyl-1)-2 ethanol
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
FR2694555A1 (fr) * 1992-08-05 1994-02-11 Synthelabo Procédé de péparation des énantiomères du 1-(4-chloro-2-hydroxyphényl)-2-[4-[(4-fluorophényl)méthyl]-piperidin-1-yl]éthanol.
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

Also Published As

Publication number Publication date
AU2492295A (en) 1996-01-25
HU9502113D0 (en) 1995-09-28
EP0692472A1 (fr) 1996-01-17
KR960004322A (ko) 1996-02-23
IL114562A (en) 1999-11-30
JPH0859616A (ja) 1996-03-05
SK88795A3 (en) 1996-02-07
CA2153726A1 (en) 1996-01-14
IL114562A0 (en) 1995-11-27
CZ180795A3 (en) 1996-01-17
FR2722497B1 (fr) 1996-08-14
TW374084B (en) 1999-11-11
ZA955801B (en) 1996-04-25
NZ272552A (en) 1996-06-25
AU695312B2 (en) 1998-08-13
HU215599B (hu) 1999-01-28
NO304427B1 (no) 1998-12-14
NO952761D0 (no) 1995-07-12
CN1120038A (zh) 1996-04-10
PL309589A1 (en) 1996-01-22
US5620990A (en) 1997-04-15
RU95113144A (ru) 1997-06-27
HUT73137A (en) 1996-06-28
FR2722497A1 (fr) 1996-01-19
FI953410L (fi) 1996-01-14
FI953410A0 (fi) 1995-07-12
FI953410A7 (fi) 1996-01-14

Similar Documents

Publication Publication Date Title
NO985977D0 (no) Spiro-piperidinderivater og deres anvendelse som terapeutiske midler
NO963506D0 (no) 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler
NO942193D0 (no) Metallocener og fremgangsmåte til deres fremstilling og bruk
NO990551D0 (no) Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
NO991761D0 (no) Nye piperidin-kotokarbonsyre-derivater, deres fremstilling og anvendelse
NO990012L (no) Nye erytromyciner og fremgangsmÕte for deres fremstilling
DK641589D0 (da) N-aryl-azetidinoner, fremgangsmaade til deres fremstilling og deres anvendelse som elastaseinhibitorer
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
NO20003067L (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
NO981522L (no) Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister
NO994510L (no) Substituerte isokinolin-derivater og deres anvendelse som antikonvulsanter
DK0764157T3 (da) Benzopyraner og deres anvendelse som terapeutiske midler
NO985307L (no) Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvende
DK0795547T3 (da) (Aminoalkyl- og acylaminoalkyl-oxy)benzyloxyquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse som bradyk
NO951418D0 (no) Peptidderivater, deres fremstilling og anvendelse som terapeutika
NO941517L (no) 2-amino-4-kinolin-dihydropyridiner, fremgangsmåter for deres fremstilling og deres anvendelse
NO922842L (no) Benzotiazolderivater, fremgangsmaate for deres fremstilling og deres anvendelse som terapeutika
NO954763D0 (no) Piperidinderivater, deres fremstilling og anvendelse
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO940130D0 (no) Benzimidazolderivater, fremgangsmaate for deres fremstilling og te rapeutisk anvendelse derav
NO955242D0 (no) Piperidinderivater, fremgangsmåte for fremstilling derav og deres terapeutiske anvendelse
NO975130L (no) <alfa>-(substituerte alkylfenyl)-4-(hydroxydifenylmethyl)-1-piperidinbutanolderivater, deres fremstilling og deres anvendelse som antihistaminer, anti-allergimidler og bronchodilatorer
NO952761D0 (no) Piperidinestere, fremgangsmåte for deres fremstilling og anvendelse som terapeutika
NO932823L (no) Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler og fremgangsmåter for deres fremstilling

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JANUARY 2001